TP53 and B-cell chronic lymphocytic leukemia: The median age was 59 years old vs. 73 years old, and there were more high-risk patients in LT-CLL-001 vs. LT-CLL-2s: TP53 mut/17p del 44% vs. 20%, IgHV unmutated, 86% vs. 68%, fludarabine refractory 34% vs. 8%.